Basecamp Wealth Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

Basecamp Wealth Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-59	Closed	-$1.38K	–	1971
2026 Q1	$1.38K	Buy	59 +50	+556%	+$1.09K	﹤0.01%	1486
2025 Q4	$189	Buy	+9	New	+$157	﹤0.01%	1703

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Basecamp Wealth Advisors's SNDX Position: Q2 2026 in Review

Basecamp Wealth Advisors sold out of Syndax Pharmaceuticals (SNDX) in Q2 2026, closing a stake of 59 shares — an estimated $1.38K sold.

Basecamp Wealth Advisors first reported a position in SNDX in Q4 2025 and held it in 2 quarters. The position peaked at $1.38K in Q1 2026. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Basecamp Wealth Advisors reported no remaining Syndax Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Basecamp Wealth Advisors sold 59 Syndax Pharmaceuticals shares in Q2 2026, an estimated $1.38K.
Basecamp Wealth Advisors first reported a position in Syndax Pharmaceuticals in Q4 2025 and held it in 2 quarters.
Basecamp Wealth Advisors's Syndax Pharmaceuticals position peaked at $1.38K in Q1 2026.
242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.